Circulating tumor DNA detection and quantification in patients with ovarian cancer.

Technique development:

In a first step, the different available techniques will be evaluated for specificity and sensibility using serial dilutions of cell lines with or without TP53 mutation.

Validation:

The tumor DNA detection rate will be estimated from patient's blood with ovarian cancer.

The investigators will study 25 patients to obtain at least 15 patients bearing a TP53 mutation that could be characterized in the primitive tumor or metastasis. With those 15 patients, the investigators will determine the most sensitive technique and the best cost/efficiency ratio.

Inclusion Criteria:

• Age > or = 18 years.
• Patient with invasive ovarian cancer stage II to IV from FIGO classification.
• Patient treated by surgery.
• Patient with tumor or metastasis available for TP53 status characterization
• Patient able to stand a blood collection.
• Signed written informed consent approved by AFSSAPS and CPP.

Exclusion Criteria:

• Patient without social protection / insurance.
• Borderline ovarian tumor.
• Non carcinoma ovarian tumor
• Patient with invasive ovarian cancer 5 years before diagnosis
• Current pregnancy and lactation.
• All social, medical, psychological, situations making the study impossible.
• Person deprived of liberty.

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).